Ulcerative Colitis and Acute Severe Ulcerative Colitis Patients Are Overlooked in Infliximab Population Pharmacokinetic Models: Results from a Comprehensive Review

Ulcerative colitis (UC) is part of the inflammatory bowels diseases, and moderate to severe UC patients can be treated with anti-tumour necrosis α monoclonal antibodies, including infliximab (IFX). Even though treatment of UC patients by IFX has been in place for over a decade, many gaps in modellin...

Descripción completa

Detalles Bibliográficos
Autores principales: Démaris, Alix, Widigson, Ella S. K., Ilvemark, Johan F. K. F., Steenholdt, Casper, Seidelin, Jakob B., Huisinga, Wilhelm, Michelet, Robin, Aulin, Linda B. S., Kloft, Charlotte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9610912/
https://www.ncbi.nlm.nih.gov/pubmed/36297530
http://dx.doi.org/10.3390/pharmaceutics14102095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9610912/
https://www.ncbi.nlm.nih.gov/pubmed/36297530
http://dx.doi.org/10.3390/pharmaceutics14102095

Ejemplares similares